
The zzso of obesity and its associated zzso have significantly increased over the years with adverse health and financial consequences for zzso zzso changes are essential for the prevention and treatment of obesity but their benefit appears limited as inadequate and zzso weight loss results have been zzso zzso is frequently advocated as part of a weight loss zzso In this review, we will discuss the zzso drugs with Food and Drug Administration approval and their cardiovascular zzso 

zzso zzso remains the single zzso that has approval in zzso zzso zzso and zzso have long been approved in the United States, whereas zzso and the extended release combination of zzso with zzso have recently gained zzso The development of single peptides targeting gut hormones or other host signals related to obesity may represent promising therapeutic zzso 

Despite the recent failures of a number of zzso drugs, the zzso of obesity is progressing zzso Treating the obese cardiovascular patient has proven zzso zzso safety and the zzso of weight loss are key areas of focus in drug development zzso 

